NCT06859775

SHR-A1811 Combination Regimen for the Treatment of Recurrent or Metastatic Cervical Cancer

Open-label, Multicenter Phase Ib/II Clinical Study of Injectable SHR-A1811 in Combination Regimens for the Treatment of Recurrent or Metastatic Cervical Cancer

• Status: Recruiting
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 100 (estimated)
• Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Industry
• Sex: Female
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

This study is a multicentre, open-label, dose-finding/efficacy-expanding phase Ib/II clinical trial to evaluate the tolerability, safety, pharmacokinetic profile and immunogenicity of SHR-A1811 combination regimen in the treatment of recurrent or metastatic cervical cancer and to preliminarily evaluate the efficacy of SHR-A1811 combination regimen for recurrent or metastatic cervical cancer.

Conditions

• Recurrent or Metastatic Cervical Cancer

Interventions

Type	Name	Description
DRUG	SHR-A1811	SHR-A1811 injection.
DRUG	Adebelimab injection	Adebelimab injection.
DRUG	Bevacizumab injection	Bevacizumab injection.
DRUG	SHR-8068	SHR-8068 injection.
DRUG	Cisplatin injection	Cisplatin injection.
DRUG	Carboplatin injection	Carboplatin injection.

Timeline

• Start date: 2025-04-25
• Primary completion: 2026-10-01
• Completion: 2027-01-01
• First posted: 2025-03-05
• Last updated: 2025-06-06

Locations

1 site across 1 country: China